According to filings with the U.S. Securities and Exchange Commission, Notable Labs is raising $10,336,259.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Thomas Bock played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Notable Labs
Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community. Notables proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a products medical impact and commercial value faster, higher, and more likely than traditional drug development.

To learn more about Notable Labs, visit http://notablelabs.com/

Contact:
Thomas Bock, Chief Executive Officer
415-851-2410
https://www.linkedin.com/in/thomasbock/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.